Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And CommercializationSeeking Alpha • 08/25/26
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026Business Wire • 08/06/26
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of PsilocybinBusiness Wire • 08/06/26
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business HighlightsBusiness Wire • 08/05/26
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026Business Wire • 07/29/26
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.The Motley Fool • 07/29/26
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapyProactive Investors • 07/17/26
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from PsychotherapyBusiness Wire • 07/16/26
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies saysProactive Investors • 07/13/26
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression TranscriptSeeking Alpha • 07/07/26
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch TimelineBenzinga • 07/07/26
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable ProfileBusiness Wire • 07/07/26
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearPRNewsWire • 06/26/26